Search

Your search keyword '"Gercheva L"' showing total 95 results

Search Constraints

Start Over You searched for: Author "Gercheva L" Remove constraint Author: "Gercheva L"
95 results on '"Gercheva L"'

Search Results

4. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL

9. Significantly higher and more rapid cytogenetic and molecular responses can be achieved in pre-treated chronic phase CML patients with high doses of Imatinib as induction therapy (800 mg/day, 6 months) - final results of a Phase III CELSG CML11 “ISTAHIT” TRIAL: V278

13. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia

14. Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma

18. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

21. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

22. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

24. PK-guided personalized prophylaxis with Nuwiq® (human-cl rh FVIII) in adults with severe haemophilia A.

27. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial

29. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study

35. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.

36. An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B.

37. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols®) with a 6-month follow up in previously treated patients with severe haemophilia B.

43. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia

44. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.

45. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.

46. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

47. Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria.

48. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

49. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

50. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).

Catalog

Books, media, physical & digital resources